Want to see GB:GENI full AI Analyst Report?
Top Page
GENinCode UK Ltd.
(LSE:GENI)
Select Model
Select Model
Rating:48Neutral
Price Target:
1.00 p
▲(11.11% Upside)
Action:Reiterated
Date:08/29/26
The score is held back primarily by weak financial performance: heavy losses, continued cash burn, and a materially weakened balance sheet (equity erosion). Technical indicators provide some support via improving short-term momentum, but valuation remains constrained by ongoing unprofitability and no dividend data.
Positive Factors
Revenue Growth
Improving revenue growth indicates stronger commercial traction and product adoption. If sustained, greater scale could help GENinCode spread fixed operating costs and move closer to profitability, although current losses show that scale benefits have not yet materialized.
Negative Factors
Deep and Persistent Unprofitability
Severe and continuing losses indicate that the current cost base is far too high for the company’s revenue scale. Without a durable improvement in operating efficiency or substantial revenue expansion, profitability remains uncertain and financial resources may continue to erode.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Improving revenue growth indicates stronger commercial traction and product adoption. If sustained, greater scale could help GENinCode spread fixed operating costs and move closer to profitability, although current losses show that scale benefits have not yet materialized.
Read all positive factors
GENinCode UK Ltd. (GENI) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£7.15M
Dividend YieldN/A
Average Volume (3M)2.67M
Price to Earnings (P/E)―
Beta (1Y)-0.64
Revenue Growth13.88%
EPS Growth15.35%
CountryUK
Employees44
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.02
Shares Outstanding753,041,140
10 Day Avg. Volume4,249,562
30 Day Avg. Volume2,672,572
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)53.10
Price to Sales (P/S)2.14
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£4.70M
GENinCode UK Ltd. Business Overview & Revenue Model
Company Description
GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technolo...
GENinCode UK Ltd. Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
35
Negative
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.08M | 2.70M | 2.16M | 1.43M | 1.15M |
| Gross Profit | 1.54M | 1.43M | 1.02M | 632.00K | 593.00K |
| EBITDA | -5.63M | -4.69M | -6.65M | -5.57M | -4.10M |
| Net Income | -5.71M | -4.43M | -7.02M | -5.56M | -4.14M |
Balance Sheet | |||||
| Total Assets | 2.38M | 2.66M | 4.19M | 11.80M | 15.21M |
| Cash, Cash Equivalents and Short-Term Investments | 895.00K | 1.17M | 2.53M | 9.75M | 14.56M |
| Total Debt | 146.00K | 234.00K | 299.00K | 354.00K | 0.00 |
| Total Liabilities | 2.25M | 1.54M | 2.90M | 3.90M | 1.49M |
| Stockholders Equity | 124.00K | 1.13M | 1.29M | 7.90M | 13.72M |
Cash Flow | |||||
| Free Cash Flow | -4.11M | -5.22M | -7.54M | -4.61M | -3.17M |
| Operating Cash Flow | -4.07M | -5.17M | -7.51M | -3.76M | -3.02M |
| Investing Cash Flow | -44.00K | 50.00K | 136.00K | -849.00K | -145.00K |
| Financing Cash Flow | 3.64M | 3.65M | -94.00K | -47.00K | 15.86M |
GENinCode UK Ltd. Technical Analysis
Neutral
0.90
Price Trends
0.88
Positive
0.97
Negative
1.30
Negative
Market Momentum
0.03
Negative
53.36
Neutral
29.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GENI, the sentiment is Neutral. The current price of 0.9 is below the 20-day moving average (MA) of 0.93, above the 50-day MA of 0.88, and below the 200-day MA of 1.30, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 53.36 is Neutral, neither overbought nor oversold. The STOCH value of 29.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:GENI.
GENinCode UK Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £27.17M | -13.10 | -55.91% | ― | 40.37% | -13.70% | |
49 Neutral | £20.87M | -1.22 | -1044.57% | ― | 65.60% | 74.84% | |
48 Neutral | £7.15M | -0.44 | -409.40% | ― | 13.88% | 15.35% | |
48 Neutral | £12.50M | -0.49 | -104.73% | ― | -56.10% | 41.10% | |
40 Underperform | £32.61M | -0.33 | -631.25% | ― | ― | ― | |
38 Underperform | £15.46M | -0.29 | -451.74% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
GB:GENI
GENinCode UK Ltd.
0.95
-0.60
-38.71%
GB:CLBX
ANGLE plc
1.10
-2.92
-72.64%
GB:GDR
Genedrive
1.33
0.61
85.06%
GB:OBD
Oxford BioDynamics
0.12
-0.31
-72.62%
GB:RENX
Renalytix
5.40
-0.45
-7.69%
GB:ABDX
Abingdon Health PLC
11.00
5.25
91.30%
GENinCode UK Ltd. Corporate Events
Business Operations and StrategyProduct-Related Announcements
GENinCode Pilot Backs Genetic Scoring for Coronary Risk in Primary Care
Positive
Aug 28, 2026
GENinCode reported preliminary real-world data from a Catalan primary care pilot showing its CARDIO inCode-Score polygenic risk test significantly refines coronary artery disease risk classification in moderate-risk patients. The study of 584 adul...
Business Operations and StrategyShareholder Meetings
GENinCode Shareholders Approve All Resolutions at Annual General Meeting
Positive
Jul 1, 2026
GENinCode Plc, a predictive genetics firm focused on cardiovascular disease and ovarian cancer prevention, develops CE-marked molecular diagnostic tests that combine clinical algorithms and bioinformatics to deliver advanced risk assessments. The ...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
GENinCode targets accelerated genetic testing scale-up as revenues rise and U.S. adoption grows
Positive
Jun 8, 2026
GENinCode reported a 14% rise in 2025 revenues to £3.1m, driven by volume growth in the U.S. and Europe and expanding adoption of its LIPID inCode and CARDIO inCode tests, despite NHS headwinds. Margins improved to 59%, though adjusted EBITDA...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.